TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
21.530
+0.380 (+1.80%)
As of 12:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close21.150
Open21.350
Bid21.480 x 2900
Ask21.490 x 1000
Day's Range21.264 - 21.670
52 Week Range10.850 - 33.820
Volume7,155,940
Avg. Volume11,319,151
Market Cap21.922B
Beta1.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Big Pharma Stocks with Huge Future Growth Potential
    InvestorPlace3 hours ago

    3 Big Pharma Stocks with Huge Future Growth Potential

    You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.

  • Benzinga5 hours ago

    Jim Cramer Gives His Opinion On Blue Apron, Teva And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer advised his viewer to hold his long position in Sirius XM Holdings Inc (NASDAQ: SIRI ). He has been recommending the stock since $4 and he is ...

  • Cramer's lightning round: I don't have a thesis for Blue Apron, so don't buy
    CNBC17 hours ago

    Cramer's lightning round: I don't have a thesis for Blue Apron, so don't buy

    Jim Cramer flies through his take on callers' favorite stocks, including a meal-kit play that's finding its footing.

  • Should You Hold Momenta (MNTA) Stock in Your Portfolio?
    Zacksyesterday

    Should You Hold Momenta (MNTA) Stock in Your Portfolio?

    Momenta (MNTA) is conducting a strategic review of its ongoing operations as revenues from Glatopa continue to decline.

  • Reutersyesterday

    Teva hopes to launch migraine drug as soon as September

    Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay. Teva and Eli Lilly are in a race to put a second migraine drug on the market, after rival Amgen won FDA approval last week for Aimovig to prevent migraine headaches in adults. Lilly has said it expects an FDA decision on its galcanezumab drug by the third quarter.

  • Reutersyesterday

    Teva Pharm says FDA to decide on migraine drug on Sept 16

    Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay. Teva had hoped to receive approval for the drug, ...

  • Warren Buffett Loves TEVA Stock and You Should Too
    InvestorPlaceyesterday

    Warren Buffett Loves TEVA Stock and You Should Too

    While Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) faded from last Wednesday highs, shares ultimately climbed about 3% that day. No, it wasn’t earnings or a new drug that gave TEVA stock a bump. Instead, it was Warren Buffett.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist2 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Benzinga5 days ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks6 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
    Zacks6 days ago

    Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

    Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

  • Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy?
    Motley Fool6 days ago

    Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy?

    America's favorite investor doubled down on a bet that this trainwreck isn't as bad as it looks. Should you follow?

  • Investopedia6 days ago

    13F: Buffett Increased Apple, Monsanto & Teva

    Warren Buffett, the billionaire investor and famed Oracle of Omaha, saw the stock portfolio of his Berkshire Hathaway decline by about $2 billion in Q1, according to recent filings with the SEC. The top five positions in Buffett's portfolio represent a whopping two thirds of the entire 13F investment package for the company. As of the end of March, AAPL was the largest portfolio stake for Berkshire Hathaway, accounting for more than 21% of the company's investments, according to its 13F filing.

  • Company News For May 17, 2018
    Zacks7 days ago

    Company News For May 17, 2018

    Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B

  • The Top Stocks Warren Buffett Is Buying Now
    Motley Fool7 days ago

    The Top Stocks Warren Buffett Is Buying Now

    It might be smart to add these Berkshire Hathaway buys to your portfolio, too.

  • Teva’s Fiscal Guidance: Confidence in Its Growth
    Market Realist7 days ago

    Teva’s Fiscal Guidance: Confidence in Its Growth

    Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.

  • Benzinga8 days ago

    Warren Buffett Pushing More Cash To Equities; 'Big 5' Stocks Still At The Top

    Warren Buffett’s Berkshire Hathaway Inc. (NYSE: BRK-A ) (NYSE: BRK-B ) filed its 13F for the first quarter on Tuesday, revealing what changes it made to its portfolio during the period. The company’s equity ...

  • Reuters8 days ago

    Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet

    ((Corrects ninth paragraph in May 15 article because of data error, and to show that Berkshire Hathaway is Apple's third-largest shareholder, trailing Vanguard Group and BlackRock, not its second-large) ...

  • Teva’s Debt Reduction Plans Progress, Targets Are on Track
    Market Realist8 days ago

    Teva’s Debt Reduction Plans Progress, Targets Are on Track

    Teva Pharmaceutical (TEVA) has been working towards paying down the high level of debt on its balance sheet. Teva obtained the debt in 2016 to fund the acquisition of Allergan’s (AGN) generic business. At the end of fiscal 2017, Teva had a net debt of $31.5 billion on its balance sheet.

  • InvestorPlace8 days ago

    Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock has been decimated over the years. This morning the stock is rallying on the news that the famed investor Warren Buffett doubled his stake in Teva stock. Wall Street loves to chase Buffett’s investments.

  • Reuters8 days ago

    Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet

    Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest ...

  • Why Did Teva Stock Increase on May 14?
    Market Realist8 days ago

    Why Did Teva Stock Increase on May 14?

    On May 14, Teva (TEVA) stock increased ~5.5% on the news of the expected delay in the FDA approval for rival Perrigo’s (PRGO) generic version of Teva’s asthma inhaler ProAir. On May 14, Teva stock closed at a trading price of $20.38 per share.

  • Analysts’ Recommendations for AstraZeneca as of May 15
    Market Realist8 days ago

    Analysts’ Recommendations for AstraZeneca as of May 15

    Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.

  • Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
    Zacks8 days ago

    Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

    Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

  • Stocks Inch Up, Dow Jones Lags; Boot Barn Spikes Out Of Buy Range
    Investor's Business Daily8 days ago

    Stocks Inch Up, Dow Jones Lags; Boot Barn Spikes Out Of Buy Range

    The Dow Jones industrials lagged Wednesday's early action as the market defended narrow gains. Teva, Macy's, Boot Barn and China's Tencent set up early leads.